Earnings summaries and quarterly performance for Sionna Therapeutics.
Executive leadership at Sionna Therapeutics.
Board of directors at Sionna Therapeutics.
BB
Bruce Booth
Detailed
Director
HE
H. Edward Fleming, Jr.
Detailed
Director
JV
Joanne Viney
Detailed
Director
JR
Joshua Resnick
Detailed
Director
LS
Laurie Stelzer
Detailed
Director
LI
Lucian Iancovici
Detailed
Director
MK
Marcella Kuhlmann Ruddy
Detailed
Director
PC
Paul Clancy
Detailed
Chairperson of the Board
PA
Peter A. Thompson
Detailed
Director
Research analysts covering Sionna Therapeutics.
Recent press releases and 8-K filings for SION.
Sionna Therapeutics Provides Update on Clinical Programs and Financial Outlook
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is focused on revolutionizing cystic fibrosis (CF) treatment using first-in-class NBD1 stabilizers.
- The company anticipates multiple data readouts and catalysts in mid-2026, including results from its Phase 2a PreciSION CF study for SION-719 and a healthy volunteer dual combination study for SION-451.
- The PreciSION CF study is designed to show a 10 millimole per liter change in sweat chloride when SION-719 is added to TRIKAFTA in F508del homozygous patients.
- Sionna Therapeutics reported $325 million in cash at the end of Q3, providing a financial runway into 2028.
Feb 11, 2026, 7:00 PM
Sionna Therapeutics Details Upcoming Clinical Catalysts and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is focused on revolutionizing Cystic Fibrosis (CF) treatment with its NBD1 stabilizers and expects multiple data readouts and catalysts in mid-2026.
- The Phase 2a PreciSION-CF study for SION-719, an NBD1 stabilizer, is designed to show a 10 millimole per liter improvement in sweat chloride when added to TRIKAFTA in F508del homozygous patients.
- A separate healthy volunteer dual combination study for SION-451 with complementary mechanisms is also anticipated to provide data in mid-2026, aiming to select the best dual combination based on tolerability and PK profiles.
- The company reported $325 million in cash at the end of Q3, providing a financial runway into 2028, within a CF market currently valued at $12 billion and projected to grow to $15 billion-$17 billion in the next five years.
Feb 11, 2026, 7:00 PM
Sionna Therapeutics Provides Clinical Pipeline and Financial Updates at Biotech Summit
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is focused on revolutionizing Cystic Fibrosis (CF) treatment using unique NBD1 stabilizers, with multiple data readouts anticipated in mid-2026.
- The Phase 2a PreciSION CF study is evaluating SION-719 added to TRIKAFTA in F508del homozygous patients, aiming for a 10 millimoles per liter improvement in sweat chloride.
- A healthy volunteer study is assessing dual combinations of SION-451 with other correctors to select a lead candidate based on tolerability and PK profiles, with results also expected in mid-2026.
- The CF market is currently valued at approximately $12 billion and is projected to grow to $15-$17 billion within the next five years.
- Sionna reported $325 million in cash at the end of 3Q, providing a cash runway into 2028.
Feb 11, 2026, 7:00 PM
Sionna Therapeutics Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is developing first-in-class NBD1 stabilizers to address the unmet need in cystic fibrosis (CF), a $12 billion market projected to grow to $15 billion+ by the end of 2030.
- The company's lead NBD1 stabilizers, SION-719 and SION-451, have both demonstrated positive Phase 1 data and are advancing to the next stages of development.
- SION-719 is currently in a Phase 2A proof-of-concept study in CF patients, with first patient data expected by mid-2026. This study aims for a 10 millimole sweat chloride improvement, which is considered clinically meaningful.
- SION-451 is serving as the anchor in a dual combination healthy volunteer study with complementary mechanisms, with data also anticipated in mid-2026.
- Sionna Therapeutics ended Q3 with $325 million in cash and has a cash runway into 2028, extending beyond these upcoming mid-2026 milestones.
Jan 13, 2026, 5:45 PM
Sionna Therapeutics Highlights Mid-2026 Data Readouts for CF Programs
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is focused on developing first-in-class NBD1 stabilizers to address the unmet need in Cystic Fibrosis (CF), a $12 billion market projected to grow to over $15 billion by 2030.
- The company's lead NBD1 stabilizers, SION-719 and SION-451, have both shown positive Phase I data and are advancing in clinical development.
- Key catalysts include data readouts in mid-2026 for SION-719 from its Phase IIA Precision CF Study in CF patients, and for SION-451 from its healthy volunteer dual combination study.
- Sionna Therapeutics reported $325 million in cash at the end of Q3, providing a cash runway into 2028, which extends beyond these critical mid-2026 milestones.
Jan 13, 2026, 5:45 PM
Sionna Therapeutics Provides Pipeline and Financial Updates at J.P. Morgan Healthcare Conference
SION
Guidance Update
New Projects/Investments
- Sionna Therapeutics is developing first-in-class NBD1 stabilizers (SION-719 and SION-451) aimed at revolutionizing the treatment of Cystic Fibrosis (CF).
- The company anticipates releasing Phase 2A proof-of-concept data for SION-719 and healthy volunteer data for SION-451 dual combination in mid-2026.
- Sionna reported $325 million in cash at the end of Q3, providing a cash runway into 2028.
- The CF market is a $12 billion monopoly, projected to grow to over $15 billion by 2030, with a significant unmet need as two-thirds of patients on current standard of care do not achieve normal CFTR function.
Jan 13, 2026, 5:45 PM
Sionna Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna is focused on transforming the standard of care in cystic fibrosis (CF) by targeting NBD1, with two primary compounds in development: SION-719 for an add-on strategy to Trikafta, and SION-451 as the anchor for a prioritized dual combination strategy.
- The company anticipates Phase 2a proof-of-concept data for SION-719 and data for the dual combination strategy with SION-451 in mid-2026.
- Sionna completed an IPO in February, raising $219 million, which provides a cash runway into 2028 and financial flexibility to execute its strategy.
- For SION-719, the company aims for at least a 10 millimole per liter change in sweat chloride, which is considered clinically meaningful and is projected to equate to approximately 3 points of FEV1.
- Sionna in-licensed three clinical-stage compounds from AbbVie, including galicaftor (2222), to expand its complementary mechanism strategy for dual combinations, with 2222 currently being evaluated in a Phase 1 healthy volunteer study in combination with 451.
Dec 4, 2025, 2:45 PM
Sionna Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna is advancing two lead NBD1 stabilizer candidates for cystic fibrosis: SION-719 in a Phase 2a proof-of-concept study as an add-on to Trikafta, and SION-451 as the anchor for a prioritized dual combination strategy, with key data readouts for both programs expected in mid-2026.
- Following its February 2025 IPO that raised $219 million, Sionna has a cash runway into 2028, providing financial flexibility to execute its strategy and pursue its goal of achieving at least a 10 millimole per liter change in sweat chloride with SION-719.
- The company targets the $12 billion cystic fibrosis market, projected to grow to $15 billion, aiming to offer new, more effective options for patients.
Dec 4, 2025, 2:45 PM
Sionna Therapeutics reviews 2025 achievements and outlines 2026 clinical milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase 1 programs for its NBD1 stabilizers, SION-719 and SION-451, in 2025, reporting positive data for both compounds.
- The company initiated a Phase 2 proof-of-concept study for SION-719 as an add-on to Trikafta and a healthy volunteer Phase 1 study for SION-451 in a dual combination with other modulators, with data for both studies anticipated in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million in gross proceeds, which provides a cash runway into 2028.
- The company's strategy focuses on improving CFTR function and normalizing sweat chloride levels, with a preferred dual combination approach, believing their NBD1 mechanism offers differentiated efficacy compared to existing treatments.
Dec 3, 2025, 5:30 PM
Sionna Therapeutics reviews 2025 accomplishments and outlines 2026 clinical milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase 1 programs for its two NBD1 stabilizers, SION-719 and SION-451, in 2025, reporting positive data.
- The company initiated a Phase 2 proof-of-concept study for SION-719 as an add-on to Trikafta and a healthy volunteer Phase 1 study for SION-451 in a dual combination, with data from both expected in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million in gross proceeds, which provides a cash runway into 2028.
- The company aims to address the unmet need in cystic fibrosis by driving more patients to normal CFTR function, noting that two-thirds of patients on current standard-of-care treatments do not achieve normal levels.
- Sionna expresses high confidence in its CFHBE assay, which has been validated by matching results with published clinical data for Vertex compounds, supporting its differentiated NBD1 mechanism.
Dec 3, 2025, 5:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more